Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05007769 |
Title | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN) |
Acronym | RAN |
Recruitment | Withdrawn |
Gender | both |
Phase | Phase II |
Variant Requirements | Yes |
Sponsors | Washington University School of Medicine |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries |
Facility | Status | City | State | Zip | Country | Details |
---|